drugset
drugset / Trial / NCT02253914

Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of BILR 355 BS Plus Low Dose Ritonavir in HIV-uninfected Male Volunteers

NCT02253914 ↗

Phase 1 Completed 100 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to determine the safety, tolerability and pharmacokinetics of BILR 355 BS plus low dose ritonavir in healthy male volunteers.

Timeline

Start
2004-02
Primary completion
2004-12
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BILR 355 BS Unknown — —
Background Ritonavir Other / unclassified — —

Indications

No indication recorded.